Futures
Access hundreds of perpetual contracts
TradFi
Gold
One platform for global traditional assets
Options
Hot
Trade European-style vanilla options
Unified Account
Maximize your capital efficiency
Demo Trading
Introduction to Futures Trading
Learn the basics of futures trading
Futures Events
Join events to earn rewards
Demo Trading
Use virtual funds to practice risk-free trading
Launch
CandyDrop
Collect candies to earn airdrops
Launchpool
Quick staking, earn potential new tokens
HODLer Airdrop
Hold GT and get massive airdrops for free
Pre-IPOs
Unlock full access to global stock IPOs
Alpha Points
Trade on-chain assets and earn airdrops
Futures Points
Earn futures points and claim airdrop rewards
US stock insider trading | Xenon Pharmaceuticals disclosed three insider trading transactions on March 13
On March 13, 2026, Xenon Pharmaceuticals (XENE) disclosed three insider transactions by company insiders. Director MORTIMER IAN sold 7,308 shares on March 13, 2026.
【Recent Insider Transactions】
【Company Profile】
Xenon Pharmaceuticals Inc. was incorporated in British Columbia on November 5, 1996 under the name of its predecessor (Xenon Bioresearch Inc.) pursuant to the Business Corporations Act (British Columbia). The company is a clinical-stage biopharmaceutical company that discovers and develops pipeline therapies for orphan diseases. The company intends to commercialize itself for a larger market and plans to establish partnerships with global pharmaceutical companies. To develop on-market (symptomatic) drugs, the company has built a core enablement discovery platform by researching rare human diseases with extreme traits, including diseases caused by ion channel mutations—also known as ion channel gene mutation diseases. The company has an integrated platform with internal functions including human genetics, small-molecule drug discovery, and preclinical and clinical development.